See more : algoWatt S.p.A. (ALW.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Pluri Inc. (PLUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluri Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Konishi Co., Ltd. (4956.T) Income Statement Analysis – Financial Results
- Bangkok Dusit Medical Services Public Company Limited (BDMS-R.BK) Income Statement Analysis – Financial Results
- Remitly Global, Inc. (RELY) Income Statement Analysis – Financial Results
- Yamato Kogyo Co., Ltd. (5444.T) Income Statement Analysis – Financial Results
- ConvaTec Group Plc (CTEC.L) Income Statement Analysis – Financial Results
Pluri Inc. (PLUR)
About Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.00K | 287.00K | 234.00K | 0.00 | 23.00K | 54.00K | 50.00K | 0.00 | 2.85M | 379.00K | 379.00K | 679.00K | 716.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00K | 9.00K | 41.59M | 50.62M | 1.57M | 2.00K | 2.00K | 2.18M | 100.00K | 13.00K | 11.00K | 20.00K | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K |
| Gross Profit | 322.00K | 278.00K | -41.36M | -50.62M | -1.55M | 52.00K | 48.00K | -2.18M | 2.75M | 366.00K | 368.00K | 659.00K | 695.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.00K |
| Gross Profit Ratio | 98.77% | 96.86% | -17,674.79% | 0.00% | -6,726.09% | 96.30% | 96.00% | 0.00% | 96.49% | 96.57% | 97.10% | 97.05% | 97.07% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.45M | 15.75M | 24.38M | 30.07M | 21.58M | 26.43M | 22.63M | 21.09M | 19.58M | 19.17M | 19.54M | 17.23M | 9.18M | 6.63M | 4.30M | 3.14M | 4.39M | 2.55M | 1.30M | 1.79M | 1.22M | 79.87K | 0.00 |
| General & Administrative | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.96K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.66K | 0.00 |
| SG&A | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 3.42M | 6.04M | 3.73M | 1.03M | 873.65K | 1.78M | 130.62K | 74.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.62K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.48M | 27.52M | 41.83M | 50.62M | 29.50M | 35.58M | 33.78M | 28.02M | 26.07M | 25.63M | 28.22M | 22.88M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Cost & Expenses | 22.48M | 27.53M | 41.83M | 50.62M | 29.50M | 35.59M | 33.78M | 28.02M | 26.17M | 25.65M | 28.23M | 22.90M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Interest Income | 1.31M | 1.08M | 581.00K | 492.00K | 384.00K | 385.00K | 276.00K | 122.00K | 149.00K | 112.00K | 246.00K | 266.00K | 575.00K | 236.00K | 2.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 866.00K | 843.00K | 887.00K | 78.00K | 196.00K | 29.00K | 937.00K | 0.00 | 100.00K | 37.00K | 36.00K | 29.00K | 12.00K | 13.00K | 31.00K | 8.00K | 0.00 | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 3.45K |
| Depreciation & Amortization | 253.00K | 362.00K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M | 2.15M | 2.07M | 1.90M | 1.03M | 435.00K | 312.00K | 207.00K | 173.00K | 129.00K | 224.72K | 264.83K | 202.85K | 153.64K | 21.04K | 0.00 |
| EBITDA | -20.23M | -27.68M | -39.43M | -48.42M | -27.39M | -33.35M | -24.05M | -25.57M | -21.01M | -22.57M | -25.03M | -21.19M | -14.35M | -10.52M | -7.23M | -6.51M | -10.35M | -7.42M | -2.10M | -1.87M | -1.84M | 0.00 | -74.45K |
| EBITDA Ratio | -6,203.99% | -8,995.12% | -17,087.18% | 0.00% | -119,800.00% | -61,924.07% | -79,958.00% | 0.00% | -743.06% | -6,255.41% | -7,033.25% | -3,081.59% | -2,003.77% | 644.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.16M | -27.25M | -41.59M | -50.62M | -29.48M | -35.53M | -33.73M | -28.02M | -23.32M | -25.27M | -27.85M | -22.22M | -15.03M | -11.11M | -7.44M | -6.56M | -10.43M | -6.28M | -2.33M | -2.83M | -3.00M | -456.96K | -74.45K |
| Operating Income Ratio | -6,796.93% | -9,493.38% | -17,774.79% | 0.00% | -128,156.52% | -65,800.00% | -67,462.00% | 0.00% | -819.07% | -6,666.75% | -7,348.28% | -3,272.90% | -2,099.30% | 660.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.00K | -1.64M | 219.00K | 758.00K | 324.00K | 225.00K | 7.61M | 205.00K | 73.00K | 590.00K | 918.00K | 1.07M | 237.00K | 266.00K | -14.00K | -84.00K | -69.00K | -2.15M | -107.46K | 731.65K | 994.18K | 0.00 | 0.00 |
| Income Before Tax | -21.34M | -28.89M | -41.37M | -49.87M | -29.15M | -35.31M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -11.07M | -7.46M | -6.64M | 0.00 | -8.24M | 0.00 | -2.09M | 0.00 | 418.26K | 0.00 |
| Income Before Tax Ratio | -6,547.24% | -10,065.16% | -17,681.20% | 0.00% | -126,747.83% | -65,383.33% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 658.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 277.00K | -351.00K | 78.00K | 196.00K | -94.00K | 7.61M | -205.00K | -73.00K | -590.00K | -918.00K | 29.00K | 249.00K | -266.00K | 14.00K | 78.00K | 69.00K | 2.15M | 107.46K | -731.65K | -994.17K | 252.51K | 77.90K |
| Net Income | -20.89M | -28.32M | -41.02M | -49.94M | -29.35M | -35.21M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -10.85M | -7.45M | -6.64M | -10.50M | -8.43M | -2.44M | -2.10M | -2.01M | -463.00K | -77.90K |
| Net Income Ratio | -6,407.36% | -9,867.94% | -17,531.20% | 0.00% | -127,600.00% | -65,209.26% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 644.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| EPS Diluted | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| Weighted Avg Shares Out | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
| Weighted Avg Shares Out (Dil) | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
Pluristem - Moment Of Truth
Pluristem's CLI Phase III trial interim results should be published soon. Results are critical and might define the fate of the company.
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported the first clinical results for PLX-R18 in humans from its...
Source: https://incomestatements.info
Category: Stock Reports